HEMATOLOGIC AND LYMPHOCYTIC DISORDER
Clinical trials for HEMATOLOGIC AND LYMPHOCYTIC DISORDER explained in plain language.
Never miss a new study
Get alerted when new HEMATOLOGIC AND LYMPHOCYTIC DISORDER trials appear
Sign up with your email to follow new studies for HEMATOLOGIC AND LYMPHOCYTIC DISORDER, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
Engineered immune cells aim to tame chronic GVHD in first human trial
Disease control TerminatedThis early-stage trial tests a new treatment called CD6-CAR Tregs for people with chronic graft-versus-host disease (cGVHD), a complication after a stem cell transplant. The therapy uses specially modified immune cells to calm the overactive immune response that causes cGVHD. The…
Matched conditions: HEMATOLOGIC AND LYMPHOCYTIC DISORDER
Phase: PHASE1 • Sponsor: City of Hope Medical Center • Aim: Disease control
Last updated May 17, 2026 05:06 UTC
-
Promising combo aims to stop leukemia from coming back
Disease control OngoingThis study tests whether a combination of two drugs, azacitidine and venetoclax, can help keep acute myeloid leukemia (AML) from returning in patients who are already in remission. About 50 adults whose leukemia is in first remission and who are not ready for a stem cell transpla…
Matched conditions: HEMATOLOGIC AND LYMPHOCYTIC DISORDER
Phase: PHASE2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated May 12, 2026 13:43 UTC
-
Can a single drug stop transplant rejection? new trial hopes to find out
Disease control OngoingThis study tests whether the drug ustekinumab can prevent acute graft-versus-host disease (GVHD) in adults receiving a stem cell transplant from an unrelated donor for blood cancers. GVHD occurs when donor cells attack the patient's body. Ustekinumab aims to calm the immune syste…
Matched conditions: HEMATOLOGIC AND LYMPHOCYTIC DISORDER
Phase: PHASE2 • Sponsor: Fred Hutchinson Cancer Center • Aim: Disease control
Last updated May 06, 2026 16:15 UTC
-
New drug may stop transplant complications in blood cancer patients
Disease control OngoingThis study tests whether adding the drug itacitinib to standard care can prevent graft-versus-host disease (GVHD) in people who have received a donor stem cell transplant for blood disorders. GVHD happens when donor cells attack the patient's body. The trial includes 31 adults ag…
Matched conditions: HEMATOLOGIC AND LYMPHOCYTIC DISORDER
Phase: PHASE2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated May 05, 2026 11:54 UTC